Ural crude oil prices diverge, market remains interested in procurement
智通财经2026/10/08 14:08(1) According to quotations, Urals crude currently has a premium of about $10 per barrel over spot Brent, inferred to be the landed price at Indian ports. (2) Meanwhile, institutional assessments show that in early October, Urals crude FOB from Russian ports was trading at a discount of around $35 per barrel, compared to about $29.5 per barrel in September. (3) These discount changes have undoubtedly been affected by the general increase in shipping costs, but the net price is still about $92 per barrel. (4) There is no single price for Urals crude; various quotations appear to come from unnamed traders. (5) Despite the threat of new U.S. sanctions, global demand for Russian or other origin crude, particularly those with higher diesel yields—such as Urals and ESPO blend crude—remains relatively resilient. (6) From a logical perspective, the divergence in quotations reflects multiple pricing factors, including transportation, sanctions, and quality differences, while the strong demand for crudes with high diesel yields provides underlying support. (7) Looking ahead, key areas of focus include the enforcement intensity of sanctions, the direction of shipping costs, and changes in the purchasing pace of major buyers such as India.
- According to some quotations, Urals crude oil is trading at an approximate premium of $10 per barrel over prompt Brent, which is believed to reflect the cost and freight (CFR) price at Indian ports.
- At the same time, institutional assessments indicate that in early October, the discount for Urals crude FOB Russian ports was about $35 per barrel, compared to approximately $29.5 in September.
- This change in discounts is undoubtedly affected by the general rise in shipping costs, but the net price remains around $92 per barrel.
- There is no single fixed price for Urals crude oil; various quotations appear to come from unnamed traders.
- Despite the threat of new US sanctions, there still seems to be some willingness in the global market to purchase Russian or other origin crude oil, especially grades with higher diesel yields—both Urals and ESPO blend fall into this category.
- Logically, the divergence in quotations reflects multi-layered pricing stemming from differences in shipping, sanctions, and crude quality, and the resilient demand for high diesel yield grades provides support.
- The key points to watch going forward are the strictness of sanction enforcement, trends in shipping costs, and changes in the procurement pace of major buyers such as India.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated Version 3 - Viatris Bets on the Non-Opioid Pain Medication Sector with a $1.65 Billion Acquisition of Pacira
Viatris has proposed an acquisition price of $36.50 per share, representing a 44.8% premium over Pacira’s last closing price. This acquisition will drive Viatris’ transition from the generic drug business to the field of patented pharmaceuticals. The company stated that the transaction is expected to be completed by the end of 2026 and will immediately enhance its financial metrics. On Thursday, Siddhi Mahatole from Reuters reported that pharmaceutical company Viatris (VTRS.O) announced a $1.65 billion cash acquisition of Pacira BioSciences (PCRX.O), aiming to add two non-opioid pain medications to its portfolio and expand beyond its core generic drugs into the high-value branded drug market. Viatris will acquire Pacira at $36.50 per share, a 44.8% premium over its last trading day closing price. In early trading, Pacira’s stock surged around 44%, while Viatris shares fell nearly 2%. Oppenheimer analyst Les Sulewski commented that the premium was “full price” and noted limited antitrust risk. He mentioned that Pacira has faced pressure from activist investors since November 2025, and with the stock close to the offer price, investors appear confident the deal will close with limited expectations for a higher bid. Through this transaction, Viatris will obtain Pacira’s “Exparel” (for the management of acute postsurgical pain) and “Zilretta” (for pain associated with osteoarthritis of the knee). In 2025, these two products are expected to achieve net sales of $575.1 million and $116.6 million respectively. Viatris stated it plans to promote these drugs in select international markets, seeking new growth drivers while deepening its presence in the patented drug segment. CEO Scott Smith said the acquisition “creates synergies with our fast-acting Meloxicam market opportunity and positions us as a leader in non-opioid pain therapeutics.” The US Food and Drug Administration is expected to decide by December 27 whether to approve Viatris’ rapid-acting Meloxicam for the treatment of moderate to severe acute pain. Viatris said it plans to mainly use excess cash to finance the acquisition, with the remainder raised through short-term borrowing. The company noted the deal will have a minimal impact on its overall leverage. Previously, Viatris raised its annual adjusted profit forecast in August thanks to strong branded drug sales and growth in the Chinese market. However, the company continues to face pressures from manufacturing setbacks in India, including a fire at its Nashik plant, as well as intense competition in the generics market. Both parties expect the deal to be completed by the end of 2026. Viatris said the acquisition will immediately improve its financial guidance metrics.
The United States suspends Microsoft’s PERM program, pressuring the company to hire American workers.
US Vice President Vance: The United States has suspended Microsoft’s (MSFT.US) “Permanent Labor Certification (PERM)” program. This move is intended to convey to Microsoft the message that it must hire American workers.
【US Stock Moves】Securitize surged on October 8: US stock tokenization launched + Solana
Crypto prices
More
